Phase 1/2, Double Blind Randomized Placebo Controlled Study to Assess the Safety and Efficacy of BGC101 (EnEPC) in the Treatment of PAD & CLI
Phase of Trial: Phase I/II
Latest Information Update: 19 Jul 2018
At a glance
- Drugs BGC-101-BioGenCell (Primary)
- Indications Peripheral arterial occlusive disorders; Peripheral vascular disorders
- Focus Adverse reactions; First in man
- Sponsors BioGenCell
- 12 Jul 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 12 Jul 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 05 Oct 2017 New trial record